The Nvidia-China dance continues - 24/7 Wall St.[S&P 5006,960.20 +0.14%][Dow Jones50,222.00 +0.16%] [Nasdaq 10025,260.80 +0.17%][Russell 20002,686.05 +0.49%][FTSE 10010,477.20 -0.41%][Nikkei 22557,739.20 -0.80%][Investing]# The Nvidia-China dance continues### Quick ReadNvidia (NVDA) shares jumped 9.11% on signals Washington may ease export restrictions on older AI chips to China.Nvidia recorded zero H20 chip sales to China in Q2 FY26 due to export restrictions.Eased export restrictions represent a $5B to $1 ...

每经AI快讯，2月12日，洲际交易所（ICE）纽约可可期货下跌近4%，至每吨3717美元。 ...

每经AI快讯，2月12日，国内商品期货夜盘开盘涨跌不一，沪金跌0.38%，沪银跌2.56%，沪铜跌 0.63%，沪铝涨0.59%，沪镍跌1.58%，铁矿跌0.46%，原油跌1.56%，橡胶跌0.54%。 ...

(A joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock Code 股份代號 : 6600) 13 February 2026 Dear non-registered shareholder(s), As a non-registered shareholder, if you wish to receive Corporate Communications from the Company pursuant to the Listing Rules, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the "Intermediaries") and provide your e ...

​Utz Brands, Inc. (NYSE:UTZ) is one of the Overlooked Small Cap Stocks to Buy Now. Utz Brands, Inc. (NYSE:UTZ) is set to release its fiscal Q4 2025 results on February 12, 2026. Wall Street expects the company to post quarterly revenue around $344.65 million along with a GAAP EPS of $0.27. Wall Street is bullish on the stock ahead of the earnings with 73% of the 11 analysts covering the stock maintaining a Buy rating. ​Recently, on January 27, Scott Marks CFA from Jefferies reiterated a Buy rating on Utz ...

Since PDD Holdings ( PDD ) was last covered (HOLD rating), the stock is up over 70% despite facing an onslaught of challenges in both their home market as well as internationally. In China, they are battling aAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PDD over the next 72 hours. I wrote this article myse ...

​Standard Motor Products, Inc. (NYSE:SMP) is one of the Overlooked Small Cap Stocks to Buy Now. On February 2, Standard Motor Products, Inc. (NYSE:SMP) announced that its Board of Directors approved an increase in quarterly dividend from 31 cents to 33 cents per share. The increase represents 6.5% rise from the previous quarterly dividend and will be payable on March 2, 2026. ​That said, Standard Motor Products, Inc. (NYSE:SMP) is expected to release its fiscal Q4 2025 results on February 20, 2026. Wall S ...

Getty Realty Corp. (NYSE:GTY) is one of the Overlooked Small Cap Stocks to Buy Now. Getty Realty Corp. (NYSE:GTY) is set to release its fiscal Q4 2025 results on February 11, 2026. Wall Street expects the company to post quarterly revenue around $55.94 million, along with a GAAP EPS of $0.34. ​Recently on January 8, the company provided its 2025 business update and initial 2026 guidance. Management noted that in 2025 the company invested roughly $269 million at an initial cash yield of 7.9%. In Q4 2025 (t ...

​Orion Group Holdings, Inc. (NYSE:ORN) is one of the Overlooked Small Cap Stocks to Buy Now. Recently, on February 6, DA Davidson maintained a Buy rating on Orion Group Holdings, Inc. (NYSE:ORN) and raised the price target from $13 to $15. On February 5, Liam Burke from B. Riley Securities also reiterated a Buy rating on the stock and raised the price target from $11.5 to $15.5. ​The bullish sentiment follows the company’s acquisition of J.E. McAmis, Inc. and its affiliate JEM Marine Leasing LLC on Febru ...

Financial Performance - Total expenses for Q2 2026 were $13.4 million, up from $10.8 million in Q2 2025, reflecting a 24% increase year-over-year[9] - Net loss attributable to shareholders for Q2 2026 was $11.8 million, or $(0.26) per share, compared to a net loss of $9.6 million, or $(0.26) per share in Q2 2025[10] - Total stockholders' equity increased to $187.4 million as of December 31, 2025, compared to $97.3 million as of June 30, 2025[12] - As of December 31, 2025, the company had $189 million in cash and cash equivalents, a significant increase from $97.7 million as of June 30, 2025[12] - There are ongoing losses and future revenue uncertainties, with a need for additional financing depending on market conditions[18] Research and Development - Research and development expenses were $5.8 million, consistent with $5.4 million in Q2 2025, indicating a 7% increase[9] - The company is focused on developing and potentially commercializing its product candidates, with ongoing clinical trials and preclinical studies[18] - The company is exploring the development of novel AAV vectors and potential future out-licenses and collaborations[18] - The company is assessing the efficacy and safety of its products, as well as those of its collaboration partners, in the marketplace[18] Clinical Trials and Studies - All four patients in Cohort 1 of the BB-301 study were formal responders at the 12-month follow-up, demonstrating a durable response[4] - Patient 1 from Cohort 1 showed continued disease-modifying effects at the 24-month follow-up, with improvements in post-swallow residue and dysphagic symptom burden[6] - The first patient in Cohort 2 was treated with a higher dose of BB-301 in Q4 2025, with interim results expected in mid-2026[7] - The FDA granted Fast Track Designation for BB-301 in November 2025, following positive interim clinical results[8] - The company plans to engage with the FDA in mid-2026 to confirm the pivotal study design for BB-301[8] Risks and Challenges - There are risks related to patient enrollment and dosing in future clinical trials, which may affect the timing of data availability[18] - Regulatory approvals and determinations by the FDA and other authorities are critical to the company's future operations[18] - The company is addressing identified material weaknesses in its internal controls over financial reporting[18] - The company is dependent on relationships with collaboration partners and third parties for its success[18] - Market competition and sales, marketing, manufacturing, and distribution requirements are significant factors impacting the company's performance[18] - The company disclaims any obligation to update forward-looking statements, highlighting the inherent uncertainties in its projections[18]